Aerie Pharmaceuticals Inc. (AERI)

19.08
0.15 0.79
NASDAQ : Health Technology
Prev Close 18.93
Open 18.65
Day Low/High 18.41 / 19.39
52 Wk Low/High 17.51 / 50.10
Volume 384.25K
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 46.32M
Market Cap 844.43M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aerie Pharmaceuticals Announces Deerfield's Conversion Of Convertible Notes Into Aerie Common Stock And Establishment Of An Undrawn $100M Credit Facility With Deerfield

Aerie Pharmaceuticals Announces Deerfield's Conversion Of Convertible Notes Into Aerie Common Stock And Establishment Of An Undrawn $100M Credit Facility With Deerfield

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Aerie Pharmaceuticals Announces Appointment Of Randall Brown As Director, Payer Marketing

Aerie Pharmaceuticals Announces Appointment Of Randall Brown As Director, Payer Marketing

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals Has Broken Out on the Upside

Aerie Pharmaceuticals Has Broken Out on the Upside

Let's review the latest charts and indicators to see where we can get positioned from the long side.

Aerie Pharmaceuticals Announces Appointment Of William Coppola As Intellectual Property Counsel

Aerie Pharmaceuticals Announces Appointment Of William Coppola As Intellectual Property Counsel

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals To Present At The JMP Securities 2018 Life Science Conference

Aerie Pharmaceuticals To Present At The JMP Securities 2018 Life Science Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals To Present At The NASDAQ 38th Investor Conference

Aerie Pharmaceuticals To Present At The NASDAQ 38th Investor Conference

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals Announces Appointment Of Concetta Perro As Commercial Counsel

Aerie Pharmaceuticals Announces Appointment Of Concetta Perro As Commercial Counsel

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,...

Aerie Pharmaceuticals To Announce First Quarter 2018 Financial Results And Host Conference Call On Tuesday, May 8, 2018

Aerie Pharmaceuticals To Announce First Quarter 2018 Financial Results And Host Conference Call On Tuesday, May 8, 2018

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018.

Aerie Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference

Aerie Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals To Present At The Oppenheimer & Co. 28th Annual Healthcare Conference

Aerie Pharmaceuticals To Present At The Oppenheimer & Co. 28th Annual Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference

Aerie Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Business Update And 2018 Guidance

Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Business Update And 2018 Guidance

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Wednesday, February 28, 2018

Aerie Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Wednesday, February 28, 2018

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its fourth quarter and full year 2017 financial results will be released after the market closes on Wednesday, February 28, 2018.

Aerie Pharmaceuticals Announces Appointment Of John LaRocca As General Counsel

Aerie Pharmaceuticals Announces Appointment Of John LaRocca As General Counsel

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces Appointment Of Scott Cassady As Regional Sales Director For The Central Region

Aerie Pharmaceuticals Announces Appointment Of Scott Cassady As Regional Sales Director For The Central Region

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces Appointment Of Brad Fuller As Director Of National Accounts In Its Market Access Department

Aerie Pharmaceuticals Announces Appointment Of Brad Fuller As Director Of National Accounts In Its Market Access Department

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces Appointment Of Tad Heitmann As Head Of Communications

Aerie Pharmaceuticals Announces Appointment Of Tad Heitmann As Head Of Communications

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces Public Offering Of Common Stock

Aerie Pharmaceuticals Announces Public Offering Of Common Stock

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma or ocular...

5 'Strong Buy' Stocks From Wall Street's Best-Performing Analysts

5 'Strong Buy' Stocks From Wall Street's Best-Performing Analysts

Despite the red-hot stock market, there remains some good buys. Here are several names to consider, one of them being Chinese eCommerce giant Alibaba.

Aerie Pharmaceuticals Announces Appointments Of Nils Hauptmann As Director Of Regulatory Affairs And Pharmacovigilance And Tim Swan As Director Of Sales And Transparency Operations

Aerie Pharmaceuticals Announces Appointments Of Nils Hauptmann As Director Of Regulatory Affairs And Pharmacovigilance And Tim Swan As Director Of Sales And Transparency Operations

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces Appointment Of Julia Williams As Director Of Medical Affairs

Aerie Pharmaceuticals Announces Appointment Of Julia Williams As Director Of Medical Affairs

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma...

Aerie Pharmaceuticals Announces U.S. FDA Approval Of Rhopressa® (netarsudil Ophthalmic Solution) 0.02% For The Lowering Of Elevated Intraocular Pressure In Patients With Open-Angle Glaucoma Or Ocular Hypertension

Aerie Pharmaceuticals Announces U.S. FDA Approval Of Rhopressa® (netarsudil Ophthalmic Solution) 0.02% For The Lowering Of Elevated Intraocular Pressure In Patients With Open-Angle Glaucoma Or Ocular Hypertension

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients...

Aerie Pharmaceuticals Announces Appointment Of Heather Johnson As Regional Sales Director For The Northeast Region

Aerie Pharmaceuticals Announces Appointment Of Heather Johnson As Regional Sales Director For The Northeast Region

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of Paul Bae As Vice President Of Human Resources

Aerie Pharmaceuticals Announces Appointment Of Paul Bae As Vice President Of Human Resources

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of Nhi Ong As Director Of Analytics

Aerie Pharmaceuticals Announces Appointment Of Nhi Ong As Director Of Analytics

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed To Meet Requirements Of Regulatory Filing In Japan

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed To Meet Requirements Of Regulatory Filing In Japan

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Noteworthy Tuesday Option Activity: AERI, OA, CVNA

Noteworthy Tuesday Option Activity: AERI, OA, CVNA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aerie Pharmaceuticals Inc , where a total volume of 11,652 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 264.7% of AERI's average daily trading volume over the past month, of 440,260 shares.

TheStreet Quant Rating: D- (Sell)